John M. Koomen, Ph.D.
Affiliations: | 2002 | Texas A & M University, College Station, TX, United States |
Area:
Biological Mass SpectrometryGoogle:
"John Koomen"Mean distance: 11.04 | S | N | B | C | P |
Parents
Sign in to add mentor| David H. Russell | grad student | 2002 | Texas A & M | |
| (Identification and elucidation of chemical modifications of DNA oligonucleotides using high resolution time -of -flight mass spectrometry.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Deng O, Dash S, Nepomuceno TC, et al. (2022) Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer. The Journal of Biological Chemistry. 102550 |
| Majumder A, Hosseinian S, Stroud M, et al. (2022) Integrated proteomics-based physical and functional mapping of AXL kinase signaling pathways and inhibitors define its role in cell migration. Molecular Cancer Research : McR |
| Zhang C, Smalley I, Emmons MF, et al. (2020) Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma. The Journal of Investigative Dermatology |
| Fang B, Izumi V, Rix LLR, et al. (2020) Lowering Sample Requirements to Study Tyrosine Kinase Signaling using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. e2000116 |
| Hamaidi I, Zhang L, Kim N, et al. (2020) Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metabolism |
| Davis AJ, Tsinkevich M, Rodencal J, et al. (2020) TAp63-regulated microRNAs suppress cutaneous squamous cell carcinoma through inhibition of a network of cell cycle genes. Cancer Research |
| Smalley I, Law V, Wyatt C, et al. (2020) Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Mooradian M, Cleary JM, Cohen JV, et al. (2020) CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors. Journal of Clinical Oncology. 38: 3609-3609 |
| Snyder K, Ren H, Lester D, et al. (2020) Abstract P2-04-03: The roles of fucosylation in promoting tumorigenic signaling in breast cancer Cancer Research. 80 |
| Creelan B, Wang C, Teer J, et al. (2020) Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial Cancer Research. 80 |